BioSpace News Archive

Drug Development

Seres Reports Positive Data for Microbiome-based C. Diff Therapeutic

Seres Therapeutics announced positive topline data from the pivotal Phase III ECOSPOR III trial of its oral microbiome therapy SER-109 for recurrent C. difficile infection (CDI).

August 10, 2020
·
3 min read
·
Mark Terry
Biotech Bay

GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy

Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising.

August 10, 2020
·
4 min read
·
Gail Dutton
FDA

Genentech Joins Biogen and Novartis in the Spinal Muscular Atrophy Market

Genentech, a Roche company, announced the U.S. Food and Drug Administration (FDA) had approved its Evrysdi (risdiplam) for spinal muscular atrophy (SMA) in adults and children two months of age and older.

August 10, 2020
·
4 min read
·
Mark Terry
Drug Development

Genentech’s Investigational UC Treatment Posts Mixed Results in Late-Stage Studies

A Genentech investigational ulcerative colitis treatment etrolizumab posted mixed results in its late-stage study program in patients who have moderate or severe active forms of the disease.

August 10, 2020
·
2 min read
·
Alex Keown
Drug Development

Biopharma Update on the Novel Coronavirus: August 10

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.

August 10, 2020
·
2 min read
·
BioSpace Editorial Staff
Biotech Beach

Verastem Sells Copiktra to Secura for $311 Million to Focus on KRAS Therapies

Boston-based Verastem signed a definitive deal to sell its global commercial and development rights to Copiktra (duvelisib) to Henderson, Nevada and San Diego-based Secura Bio.

August 10, 2020
·
3 min read
·
Mark Terry
Drug Development

Genentech Provides Update on Phase III Studies of Etrolizumab in People With Moderately to Severely Active Ulcerative Colitis

Etrolizumab met its primary endpoint of inducing remission versus placebo for people with ulcerative colitis in only two of three studies

August 10, 2020
·
6 min read
Business

BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, will be announcing its results for the second quarter 2020 on Tuesday 18 August 2020.

August 10, 2020
·
2 min read
Business

Nordic Nanovector Appoints Dr Christine Wilkinson Blanc as Chief Medical Officer

Nordic Nanovector ASA announces that Dr Christine Wilkinson Blanc has been appointed Chief Medical Officer with immediate effect.

August 10, 2020
·
5 min read
Biotech Beach

New study published in the Journal of the National Cancer Institute concludes that Epi proColon® is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening

Under the primary base case analysis, annual mSEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and Cologuard® every three years, albeit at a higher colonoscopy referral rate

August 10, 2020
·
4 min read